Evidence map›Paper›PMID 41568469›Full record

ArticleHaematologica2026

Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/ refractory multiple myeloma treated in Europe.

Michele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, Michel Delforge, Fernando Escalante, David Kleinman, Hans C Lee, Ravi Vij, Richard Greil, Thomas Melchardt and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Michele CavoDepartment of Medical and Surgical Sciences, University of Bologna, Bologna. michele.cavo@unibo.it.
Fredrik SchjesvoldOslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo.
Meletios DimopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul.
Michel DelforgeDepartment of Hematology, Catholic University of Leuven, Leuven.
Fernando EscalanteHematology Department, University Hospital of Leon, IBIOLEON, Leon.
David KleinmanFlaum Eye Institute, University of Rochester Medical Center, Rochester, NY.
Hans C LeeMD Anderson Cancer Center, Houston, Texas.
Ravi VijDivision of Medical Oncology, Washington University School of Medicine, St. Louis, MO.
Richard GreilDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg.
Thomas MelchardtDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg.
Elisabetta AntonioliHematology Department, Careggi Hospital, Florence.
Anna LysenOslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo.
Leena Camadoo-O'ByrneGSK, Stevenage.
Jacopo BitettiGSK, Zug.
Tim D'EstrubeGSK, London.
Mark FryGSK, Stevenage.
Julie ByrneGSK, Upper Providence, PA.
Carla Y VossenSyneos Health, Amsterdam.
Sandhya SapraGSK, Upper Providence, PA.
Victoria S BensonGSK, London.
Jorge MouroGSK, Neuchatel.
Malin HultcrantzMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41568469
PMCPMC13317878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.